“The Global Genome Editing Market was valued around US$ 4.2 Bn by 2018 and growing at a significant CAGR of 13.6% over next seven years 2019-2025 due to high occurrence of infectious diseases and cancer”
The global genome editing market accounted for US$ 4.2 Bn in 2018 and burgeoning over the forthcoming years. High occurrence of infectious diseases and cancer, increase in funding for genetic research in developed economies, rising government funding and growth in the number of genomics projects, technological improvements in the biotechnology sector and use of genome editing in specialized/personalized medicine are some key factors influencing the market growth. However, factors such as adverse public perception of genetic research and high cost of genomic equipment are the major factors hindering the market growth. In addition, high growth in emerging economies provides huge growth opportunity for the market.
Global genome editing market segmented on the basis of product, technology, application, end user and region.
Avail Sample Report of the Market @ https://www.precisionbusinessinsights.com/request-sample?product_id=16100
Zinc Finger Nuclease (ZFN) dominate the Global Genome Editing Market
Based on technology, global genome editing market is segmented zinc finger nuclease (ZFN), clustered regularly interspaced short palindromic repeats (CRISPR), transcription activator-like effector nuclease (TALEN) and others. Zinc-finger nucleases held considerable market share. Zinc-finger nucleases are synthetic restriction enzymes produced by fusing a zinc finger DNA-binding domain to a DNA-cleavage domain. They can be engineered to target specific preferred DNA sequences and this allows zinc-finger nucleases to target exclusive sequences within complex genomes.
Asia Pacific Leads the Global Genome Editing market
PBI’s global genome editing market report analyses the market in different regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. According to regional analysis. Asia Pacific accounted larger revenue share in global genome editing market with considerable CAGR. The growth in this region is due to increasing number of laboratories, huge spending on R & D and expansion of leading genome editing companies. Also, India is the major contributor for the growth of the market in this region. In addition, North America held significant market share during estimated period owing to growing focus on the development of gene therapies in the US.
Strategic Approvals are the Key Strategies Adopted by Market Players
Global genome editing market further reveals that the key players increasingly adopting strategies such as launch of newer products, frequent product approvals, and long term alliance to improve market revenue share and gaining significant geographic presence across the region. For Instance, In July 2017 Sangamo Therapeutics, Inc. received the U.S.FDA Fast Track designation for in vivo genome editing product candidates SB-318 and SB-913 to treat Mucopolysaccharidosis Type I (MPS I) and MPS II.
Key player’s profiles in the report are Cellectis S.A. (France), Applied Stemcell, Inc. (U.S.), Genscript (U.S.), Merck KGaA (Germany), Horizon Discovery Group plc(U.K.), Origene Technologies, Inc. (U.S.), System Biosciences, Inc. (U.S.), Sangamo Therapeutics, Inc.(U.S.), Thermo Fisher Scientific (U.S) and Transposagen Biopharmaceuticals, Inc.(U.S.).
For More Information @ https://www.precisionbusinessinsights.com/market-reports/global-gene-editing-market/
Precision Business Insights (PBI) in its report titled “Global Genome Editing Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2014-2018 and Forecast 2019-2025” assesses the market performance over seven years forecast period over 2019-2025. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period. Moreover, the report also includes the total revenue and volume for the market.
- Instruments and Software
- Zinc Finger Nuclease (ZFN)
- Clustered regularly interspaced short palindromic repeats (CRISPR)
- Transcription activator-like effector nuclease (TALEN)
- Cell Line Editing
- Targeted gene mutation
- Animal Genome Editing
- Plant Genome Editing
By End User
- Pharmaceutical companies
- Biotechnology Companies
- Clinical Research Organizations
- Rest of Europe
- Australia & New Zealand
- ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
- South Korea
- Rest of Asia-Pacific
- Rest of Latin America
Middle East and Africa (MEA)
- Gulf Cooperation Council (GCC) Countries
- South Africa
- Rest of MEA
Precision Business Insights is one of the leading market research and management consulting firm, run by a group of seasoned and highly dynamic market research professionals with a strong zeal to offer high-quality insights.
Senior Business Development Executive
Email @ email@example.com
Call @ +1-866-598-1553
Precision Business Insights